PRME Reports $149.2M Cash, $34.1M R&D, $17.4M G&A, $49.1M Net Loss, PM577/647 IND/CTA 2026, PM359 BLA Target 2027
Prime Medicine, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $3.40
-9.8% in 7d after detection
Post-detection moves
1h
—
1d
+3.0%
3d
+5.9%
7d
-9.8%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS